Please assess the completion status of the following clinical trial:

Trial Title: Hydroxychloroquine for the Treatment of Hidradenitis Suppurativa

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with hidradenitis suppurativa Hurley stage I or II~Exclusion Criteria:~* Current systemic immunosuppression, current use of biologic medication or use of these medications in the prior 3 months, patients with known retinal disease, hepatic disease (HCV, cirrhosis, aspartate aminotransferase or alanine aminotransferase \> 2 times the upper limit of normal), psoriasis, porphyria cutanea tarda, platelets \< 50,000/ul, leukocytes \<4000/ul, or Hb\<8g/dl), pregnant patients or women trying to conceive

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Hydroxychloroquine treatment (Type: EXPERIMENTAL): Hydroxychloroquine 200mg BID for 6 months

Based on this trial design, predict the completion outcome and termination type (if applicable).